Enhanced production of interleukin 6 in peripheral blood monocytes stimulated with mucins secreted into the bloodstream

Clinical Cancer Research

Volumn 11, Issue 17, 2005, Pages 6127-6132

  Yokoigawa, Norio ^a   Takeuchi, Noriko ^b   Toda, Munetoyo ^c   Inoue, Mizue ^c   Kaibori, Masaki ^a   Yanagida, Hidesuke ^a   Tanaka, Hironori ^a   Ogura, Tokuhiro ^a   Takada, Hideho ^a   Okumura, Tadayoshi ^a   Kwon, A H ^a   Kamiyama, Yasuo ^a   Nakada, Hiroshi ^b,c  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b KYOTO SANGYO UNIVERSITY   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; MUCIN; PLASMA PROTEIN; SCAVENGER RECEPTOR; SEPHAROSE; SIALYL TN ANTIGEN; TN ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; BINDING COMPETITION; BLOOD; BLOOD LEVEL; CANCER CELL; CHROMATOGRAPHY; CLINICAL ARTICLE; COCULTURE; COLON CANCER; CYTOKINE PRODUCTION; DOSE RESPONSE; FEMALE; HUMAN; HUMAN CELL; MALE; MONOCYTE; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PURIFICATION; RECEPTOR BINDING; TUMOR; TUMOR GROWTH;

AGED; AGED, 80 AND OVER; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CELL CULTURE TECHNIQUES; COLONIC NEOPLASMS; CULTURE MEDIA, CONDITIONED; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; MONOCYTES; MUCINS; PEPTIDE FRAGMENTS; RECEPTORS, IMMUNOLOGIC; RECEPTORS, SCAVENGER; UP-REGULATION;

EID: 24344451213     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0292     Document Type: Article

References (43)

1. Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 1993;54:1-78.
2. Plante M, Rubin SC, Wong GY, Federici MG, Finstad CL, Gastl GA. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer 1994;73:1882-8.
3. Galizia G, Lieto E, De Vita F, et al. Circulating levels of interleukin-10 and interleukin-6 in gastric and colon cancer patients before and after surgery: relationship with radicality and outcome. J Interferon Cytokine Res 2002;22:473-82.
4. Galizia G, Orditura M, Romano C, et al. Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol 2002;102:169-78.
5. Berek JS, Chung C, Kaldi K, Watson JM, Knox RM, Martinez-Maza O. Serum interleukin-6 levels correlated with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol 1991;164: 1038-42.
6. De Vita F, Romano C, Orditura M, et al. Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator. J Interferon Cytokine Res 2001; 21:45-52.
7. Bataille R, Barlagie B, Lu ZY, et al. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995;86:685-91.
8. Asschert JG, Vellenga E, Ruiters MH, de Vries EG. Regulation of spontaneous and TNF/IFN-induced IL-6 expression in two human ovarian-carcinoma cell lines. Int J Cancer 1999;82:244-9.
9. James SG, Anne MB, Eldo F, Alexandra B, Michael TL, Sally EC. Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma. Ann Surg 1998; 227:398-404.
10. Dosquet C, Schaetz A, Fraucher C, et al. Tumor necrosis factor-α, interleukin-1 β, and interleukin-6 in patients with renal cell carcinoma. Eur J Cancer 1994;30:162-7.
11. Gallo O, Gori AM, Attanasio M, Martini F, Fini-Storchi O, Abbate R. Interleukin-6 serum level and monocyte production in head and neck cancer. Br J Cancer 1992;65:479-80.
12. Fearon KC, McMillan DC, Preston T, Winstanley FP, Cruickshank AM, Shenkin A. Elevated circulating interleukin-6 is associated with an acute-phase response but reduced fixed hepatic protein synthesis in patients with cancer. Ann Surg 1991;213:26-31.
13. Falconer JS, Fearon KC, Plester CE, Ross JA, Carter DC. Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg 1994;219:325-31.
14. Piancatelli D, Romano P, Sebastiani P, Adorno D, Casciani CU. Local expression of cytokines in human colorectal carcinoma: evidence of specific interleukin-6 gene expression. J Immunother 1999;22:25-32.
15. Schneider MR, Hoeflich A, Fischer JR, Wolf E, Sordat B, Lahm H. Interleukin-6 stimutates clonogenic growth of primary and metastatic human colon carcinoma cells. Cancer Lett 2000;151:31-8.
16. Shirota K, LeDuy L, Yuan SY, Jothy S. Interleukin-6 and its receptor are expressed in human intestinal epithelial cells. Virchows Arch B Cell Pathol Incl Mol Pathol 1990;58:303-8.
17. Herbeuval JP, Lelievre E, Lambert C, Dy M, Genin C. Recruitment of STAT3 for production of IL-10 by colon carcinoma cells induced by macrophage-derived IL-6. J Immunol 2004;172:4630-6.
18. Shimura S, Yang G, Ebara S, Wheeler TM, Frolov A, Thompson TC. Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res 2000;60: 5857-61.
19. Smith K, Bui TD, Poulsom R, Kaklamanis L, Williams G, Harris AL. Up-regulation of macrophage wnt gene expression in adenoma-carcinoma progression of human colorectal cancer. Br J Cancer 1999;81:496-502.
20. Kim YS, Gum J Jr, Brockhausen I. Mucin glycoproteins in neoplasia. Glycoconj J 1996;13:693-707.
21. Miyake M, Taki T, Hitomi S, Hakomori S. Correlation of expression of H/Le(y)/Le(b) antigens with survival in patients with carcinoma of the lung. N Engl J Med 1992;327:14-8.
22. Inaba T, Sano H, Kawahito Y, et al. Induction of cyclooxygenase-2 in monocyte/macrophage by mucins secreted from colon cancer cells. Proc Natl Acad Sci U S A 2003;100:2736-41.
23. Doi T, Higashino K, Kurihara Y, et al. Charged collagen structure mediates the recognition of negatively charged macromolecules by macrophage scavenger receptor. J Biol Chem 1993;268:2126-33.
24. Bordin L, Priante G, Musacchio E, et al. Arachidonic acid-induced IL-6 expression is mediated by PKCα activation in osteoglastic cells. Biochemistry 2003; 22:4485-91.
25. Hershko DD, Robb BW, Luo G, Hasselgren PO. Multiple transcription factors regulating the IL-6 gene are activated by cAMP in cultured Caco-2 cells. Am J Physiol Regul Integr Comp Physiol 2002;283: 1140-8.
26. Odemis V, Moepps B, Gierschik P, Engele J. Interleukin-6 and cAMP induce stromal cell-derived factor-1 chemotaxis in astroglia by up-regulating CXCR4 cell surface expression. Implications for brain inflammation. J Biol Chem 2002;18:39801-8.
27. Hsu HY, Hajjar DP, Khan KM, Falcone DJ. Ligand binding to macrophage scavenger receptor-A induces urokinase-type plasminogen activator expression by a protein kinase-dependent signaling pathway. J Biol Chem 1998;9:1240-6.
28. Tanaka N, Nakada H, Inoue M, Yamashina I. Binding characteristic of an anti-Sia-α-2-6GalNAc-α-Ser/Thr (sialyl Tn) monoclonal antibody (MLS 132). Eur J Biochem 1999;263:27-32.
29. Schneider C, Newman RA, Sutherland DR, Asser U, Greaves MF. A one-step purification using a high efficiency immunomatrix. J Biol Chem 1982;25: 10766-9.
30. McCool DJ, Forstner JF, Forstner GG. Synthesis and secretion of mucin by the human colonic tumour cell line LS180. Biochem J 1994;302:111-8.
31. Vitolo D, Zerbe T, Kanbour A, Dahl C, Herberman RB, Whiteside TL. Expression of mRNA for cytokines in tumor-infiltrating mononuclear cells in ovarian adenocarcinoma and invasive breast cancer. Int J Cancer 1992;51:573-80.
32. Kodama T, Reddy P, Kishimoto C, Krieger M. Purification and characterization of a bovine acetyl low density lipoprotein receptor. Proc Natl Acad Sci U S A 1988;85:9238-42.
33. Kodama T, Freeman M, Rohrer L, Zabrecky J, Matsudaira P, Krieger M. Type I macrophage scavenger receptor contain α-helical and collagen-like coiled coils. Nature 1990;43:531-5.
34. Yoshiizumi K, Nakajima F, Dobashi R, Nishimura N, Ikeda S. Studies on scavenger receptor inhibitors. Part 1. Synthesis and structure-activity relationships of novel derivatives of sulfatides. Bioorg Med Chem 2002;10:2445-60.
35. Becker C, Fantini MC, Schramm C, et al. TGF-β suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004;21: 491-501.
36. Motro B, Itin A, Sachs L, Keshet E. Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis. Proc Natl Acad Sci U S A 1990;87:3092-6.
37. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83: 493-501.
38. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998;58:362-6.
39. Plescia OJ, Smith AH, Grinwich K. Subversion of immune system by tumor cells and role of prostaglandins. Proc Natl Acad Sci U S A 1975;72:1848-51.
40. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, Jothy S. Expression of prostaglandin G/ H synthase-1 and -2 protein in human colon cancer. Cancer Res 1995;55:2556-9.
41. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-16.
42. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 1997;94: 3336-40.
43. Barnd DL, Lan MS, Metzgar RS, Finn OJ. Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic Tcells. Proc Natl Acad Sci U S A 1989;86:7159-63.